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Abstract
7C8 is a mouse monoclonal antibody specific for the third hypervariable region (V3) of the human immunodeficiency virus
type 2 (HIV-2)-associated protein gp125. The three-dimensional crystal structure of the Fab fragment of 7C8, determined to
2.7 A ˚ resolution, reveals a deep and narrow antigen-binding cleft with architecture appropriate for an elongated epitope.
The highly hydrophobic cleft is bordered on one side by the negatively charged second complementarity determining
region (CDR2) and the unusually long positively charged CDR3 of the heavy chain and, on the other side, by the CDR1 of the
light chain. Analysis of 7C8 in complex with molecular models of monomeric and trimeric gp125 highlights the importance
of a conserved stretch of residues FHSQ that is localized centrally on the V3 region of gp125. Furthermore, modeling also
indicates that the Fab fragment neutralizes the virus by sterically impairing subsequent engagement of the gp125 trimer
with the co-receptor on the target cell.
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Introduction
The human immunodeficiency virus 2 (HIV-2) was first
described in the mid 1980s. It is closely related to HIV-1 and
has a very similar genomic organization [1]. Nevertheless, the
sequence identity of the two viruses is limited and HIV-2 is less
pathogenic in humans. The transmission frequency of HIV-2 is
reduced and infection results in lower viral load and longer latency
with markedly slower progression to AIDS when compared to
HIV-1 [2,3]. Importantly, and in contrast to HIV-1, HIV-2 was
also found to be relatively more susceptible to antibody
neutralization [2].
The HIV-2 envelope proteins gp36 and gp125 are the main
targets for neutralizing antibodies [4]. Although the crystal
structures of gp36 and gp125 have not been determined yet,
functional and structural studies suggest strong similarities to their
HIV-1 homologues gp41 and gp120, respectively [2,5]. As in
HIV-1, they mediate viral fusion via binding to CD4 and a co-
receptor, mainly CCR5 or CXCR4, on the target cell. The HIV
envelope proteins assemble into surface spikes composed of trimers
of non-covalent gp36-gp125 heterodimers, with gp36 traversing
the viral membrane and anchoring the gp36-gp125 complex to the
virus [6,7]. The sequence of the heavily glycosylated gp125 protein
is highly variable, especially within its five variable regions
designated V1 to V5 that are considered crucial elements of
neutralization resistance [8,9].
The third variable region, V3, of gp125 consists of 35 amino
acid residues presumably forming an exposed and flexible region
linked at its base by a disulfide bridge between the cysteine
residues C311 and C344 (according to the SIV Mac239
enumeration, http://www.hiv.lanl.gov). The V3 region is of
crucial importance for co-receptor binding and determines, at
least partially, the tropism of the virus [10,11,12]. Furthermore,
infected individuals and animals frequently display high titers of
neutralizing antibodies against V3. Accordingly, the V3 regions of
gp120 and gp125 have been described as principal neutralization
determinants for antibody responses against both viruses
[13,14,15]. However, especially in HIV-1, this region is assumed
to be partially masked prior to CD4 engagement and prone to
escape from neutralization [10]. Conversely, the V3 region of
gp125 in HIV-2 was found to be generally less variable and more
accessible, which might contribute to its reduced neutralization
resistance [10,16].
For HIV-1, information derived from structural studies of Fab
fragments of V3-specific antibodies, combined with the determi-
nation of the crystal structure of the V3-containing gp120 core,
have contributed to a better understanding of epitope binding and
of the structural basis for neutralization breadth
[17,18,19,20,21,22,23]. In contrast, no similar structural informa-
tion has been hitherto gathered for HIV-2, especially in the light of
its disparate V3 sequence, lower resistance to neutralization and
tendency for CD4 independence.
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previously described in the V3 region of gp125, corresponding to
the stretches of residues 330–333 (FHSQ) and 343–345 (WCR)
[24,25,26,27]. FHSQ- and WCR-specific HIV-2 neutralizing V3-
specific murine monoclonal antibodies have been isolated from
animals immunized with V3-derived peptides [26,27,28]. The
monoclonal antibody 7C8 binds to V3-peptides corresponding to
the stretch of residues 326 to 341 that contains the FHSQ epitope
[27,29,30]. Interestingly, the third complementarity determining
region of the heavy chain (CDRH3) of 7C8 comprises 13 amino
acid residues while the majority of CDRH3 domains from murine
IgG1 are only 8 to 9 residues long [30,31,32]. This concords well
with data from human neutralizing antibodies specific for gp120
and suggests an important role for the elongated CDRH3 loops.
In this study the crystal structure of the Fab fragment of 7C8 is
presented, providing the first structural analysis of an HIV-2-
neutralizing antibody. The three-dimensional structure of 7C8
reveals a deep and narrow highly hydrophobic antigen-binding
site, bordered by the unusually long CDRH3 and the two CDRH2
and CDRL1 loops. A potential mechanism for viral neutralization
through sterical hindrance by the 7C8 Fab fragment is proposed
based on molecular modeling of the complex of 7C8 with the
gp125 trimer.
Results and Discussion
Determination of the crystal structure of the Fab
fragment of 7C8
The three dimensional structure of the Fab fragment of the
HIV-2-neutralizing V3-specific monoclonal antibody 7C8 was
determined to a resolution of 2.7 A ˚ (Table 1) with Rcryst and Rfree
factor values of 22.6% and 27.3%, respectively. The asymmetric
unit includes two 7C8 Fab molecules, 78 water molecules and one
glycerol molecule. The model displays good stereochemistry with
the exception of the valine residue V51 found in the disallowed
region of the Ramachandran plot in both 7C8 monomers. Valine
V51 is the i+1 residue of a distorted turn forming the CDRL2 loop
and its deviation from ideal geometry is commonly found in crystal
structures of Fab fragments [33]. The final electron density is of
good quality with well-defined polypeptide chains. Nevertheless,
residues 127–132 are not well defined in the electron density
indicating disorder in this region. These residues form a loop in
the first constant region of the heavy chain (CH1), which is also not
well defined in crystal structures of other Fab fragments [34]. All
7C8 residues were numbered according to the Chothia numbering
scheme that compensates for length variability in the CDRs and
generates a consistent numbering of the structurally conserved Fab
framework region [35].
Overall structure of the 7C8 Fab fragment
The overall structure of the 7C8 Fab fragment comprises the
four immunoglobulin domains VL,V H,C L and CH1 that form the
variable (V) and constant (C) domains of the light (L) and heavy
chains (H) (Figure 1A). Two pairs of disulfide bridges are formed
between cysteine residues 23-88, and 134–194 in the light chain as
well as between cysteine residues 22–92 and 140–195 in the heavy
chain. The binding site of the 7C8 Fab is formed by the six
solvent-exposed CDR loops CDRH1, H2, H3, L1, L2 and L3,
which project from the b-strands of the VH and VL domains
(Figure 1A). All residues that form the six CDRs, including the
prominent side-chains of the CDRH3 residues K98 and N99, have
well-defined electron density (Figure 1B).
The elbow angle, which is commonly used to describe the
relative orientation of the variable versus the constant domains of
each Fab fragment, differed significantly between the two 7C8
molecules present in the asymmetric unit with 138u and 184u for
7C8 monomer 1 (chains A and B) and monomer 2 (chains H and
L), respectively (Figure 1C). Nevertheless, this variation lies within
the range commonly found for Fab fragments with a kappa light
chain [36]. The flexibility of the elbow likely reflects an adaptation
to circumvent potential sterical hindrance and to allow bivalent
binding for large immunoglobulins [36]. Packing of the two 7C8
monomers in the asymmetric unit results in a limited number of
crystal contacts including interactions that possibly favor the
observed differences in elbow angle and the stabilization of the
CDRs (data not shown). However, it should be noted that the
conformation of all the residues comprising the six CDR loops is
Table 1. Data collection and refinement statistics.
Statistics of diffraction data
Wavelength (A ˚)0 . 9 7 A ˚
Resolution (A ˚) 44.6–2.7 (2.85–2.7)
Space group P3221
Unit-cell parameters (A ˚) a=b=100.1, c=196.8
VM (A ˚3 Da
-1) 3.03
Solvent content (%) 59
No. of molecules in ASU 2
No. of observed reflections 245681 (31362)
a
No. of unique reflections 32045 (4588)
Redundancy 7.7 (6.8)
Completeness (%) 99.9 (99.9)
Rmerge
b (%) 7.0 (62.1)
ÆI/s(I)æ 21.1 (2.3)
Statistics of refinement and structure model
Rcryst
c (%) 22.6
Rfree
d (%) 27.3
Number of protein atoms 6677
Number of water molecules 78
Number of glycerol molecules 1
RMSD from ideal geometry
bond lengths (A ˚)0 . 0 0 7
bond angles (u)1 . 0 6 5
Average B factor (A ˚2)
e
Residues 88
Water 29
Glycerol 93
Ramachandran plot (%)
Most favored regions 90
Allowed regions 9.6
Generously allowed regions 0.1
Disallowed regions 0.3
aNumber in parentheses indicate the outer-resolution shell.
bRmerge = ghkl gi |Ii (hkl)-ÆI (hkl) æ|/ghkl gi Ii (hkl), where Ii(hkl)i st h eith
observation of reflection hkl and ÆI (hkl) æ is the weighted average intensity for
all observations i of reflection hkl.
cRcryst = Shkl = ghkl|Fobs 2 Fcalc|/Shkl |Fobs|.
dRfree is the same as Rcryst except for 5% of the data excluded from the
refinement.
eSum of the TLS and Residual B-factor contributions.
doi:10.1371/journal.pone.0018767.t001
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asymmetric unit.
The deep and narrow hydrophobic antigen-binding site
of 7C8, bordered by the unusually long CDRH3 domain,
is well fitted for binding of an elongated epitope
Five of the six CDRs in 7C8 (H1, H2, L1, L2 and L3) display
conformations that correspond to canonical classes 1, 2, 4, 1 and 1,
respectively (Figure 2) [37]. The CDRH3 loop of 7C8 comprises
13 amino acid residues and is therefore elongated with respect to
the average length (8–9 residues) of mural IgG molecules
[31,32,38]. It features a kink, often found in Fab fragments of
antibodies, that results from the formation of hydrogen bond
interactions between the pairs of residues R94-D101 and M100C-
W103 [37,39] (data not shown). These canonical classes are most
commonly found in so-called peptide-binding antibodies and,
combined with shorter CDRH3 loops, are usually attributed to the
presence of a deep cleft within the antigen-binding site in contrast
to flatter antigen binding interfaces found in so-called protein-
binding antibodies [38,40]. An example of an antibody belonging
to this family is K42-41L, that shares high sequence similarity with
the heavy chain of 7C8 (80% identity), and which CDRs display
similar conformations to those found in 7C8 [41]. The Fab
fragment of K42-41L, that binds a loop on rhodopsin, was
crystallized with a peptide mimic of the epitope that fits snuggly in
the peptide-binding cleft of the antibody. A similar pattern with a
conserved peptide epitope, derived from the V3-region of gp120,
running through an antigen binding cleft bordered by an
elongated CDRL1 and a much shorter CDRH3 has also been
described in the crystal structure of the murine anti HIV-1
antibodies 83-1 and 50-1 [42,43].
Nevertheless, and as also previously observed in the murine anti
HIV-1 V3 antibody 58.2 [44], the CDRH3 loop of 7C8, localized
at one end of its deep, narrow and highly hydrophobic cleft
(Figure 2) is unusually long. Although the rationale underlying the
apparent need for such an elongated domain is not fully
understood, one possible explanation could be that the unusual
length of CDRH3 allows for extensive contacts with the V3-
derived peptide as nicely exemplified in the crystal structure of the
human anti HIV-1 V3 antibodies 447-52D, 3074 and F425
[20,45,46]. A second non-excluding possibility could be that the
unusual length of this loop allows the antibody to overcome
potential sterical hindrance and reach its epitope with higher
affinity. In conclusion, the extended conformation of the CDRL1
and CDRH3 loops in the antigen-binding site of 7C8 may allow
extensive interactions with the V3 region of gp125 and possibly to
overcome sterical hindrance.
Qualitative analysis of the electrostatic surface potential
indicates that the two sides of the deep antigen-binding cleft are
positively and negatively charged, respectively (Figure 2). The
Figure 1. Overall three-dimensional structure of the HIV-2 neutralizing Fab fragment 7C8. A) Overall view of the crystal structure of the
7C8 Fab fragment. The light and heavy chains are displayed in light and dark grey, respectively. The six CDR loops are in dark blue (CDRL1), light blue
(CDRL2), blue (CDRL3), brown (CDRH1), red (CDRH2) and pink (CDRH3). A black dashed line indicates the disordered loop within the first constant
region of the CH1 domain. B) Stick representation of the stretch of residues 93 to 100C corresponding to the unusually long third complementary
determining region of the heavy chain (CDRH3) with the electron density carved around the model at 1.2 s. C) Ribbon representation of the two
monomers found in the assymmetric unit indicating the large variation in elbow angle.
doi:10.1371/journal.pone.0018767.g001
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V94, F96, Y96, G97, Y100A and A100B, is hydrophobic. Most of
the positively charged side of the cleft is composed by residues
K50, R94 and K98, localized on CDRL2 and CDRH3, while the
negatively charged side of the antigen-binding site is mainly
formed by the aspartate residues D33 and D54, localized on
CDRH1 and CDRH2, respectively (Figure 2). Interestingly, the
six CDRs feature a high number of tyrosine, histidine and
phenylalanine residues. The relative over-representation of
tyrosine residues seems to be a common feature for protein-
specific IgGs [38] and, similarly to what has been previously
described, such aromatic side chains could potentially play an
important function in docking and affinity of epitopes through the
creation of multiple weak interactions with the target [47,48].
In conclusion, the crystal structure of the Fab fragment of 7C8
reveals a narrow highly hydrophobic antigen-binding cleft,
surrounded by charged and aromatic residues. Although five of
the CDR loops feature canonical conformations, it should be
noted that the antigen binding-cleft of 7C8 also features an
unusually elongated CDRH3.
Molecular modeling indicates that the main epitope
FHSQ of 7C8 is exposed and localized centrally on the
stem of the V3 domain of gp125
A molecular model of the gp125 monomer was generated using
as template a crystal structure of gp120 that includes the V3 region
[18]. Additionally, a putative trimeric model of gp125 was created
using the previously published molecular model of the gp120
trimer [49] in order to study binding of 7C8 in its functional
context.
The antibody 7C8 was originally isolated from mice immunized
with a 15-mer peptide, derived from the V3 region of gp125, and
corresponding to residues 326–341 (SGRRFHSQKIINKKPR)
[27]. It has also been previously demonstrated that the specificity
of 7C8 is centered on the stretch of V3-residues 330–333 FHSQ
[50]. The molecular model of gp125 indicated that the conserved
immunodominant epitope FHSQ is localized in the middle part of
the V3 region (Figure 3A), while the trimeric model further
suggested that all residues forming the FHSQ epitope protrude
towards the solvent, readily available for binding (Figure 3B).
Interestingly, the localization of FHSQ residues does therefore not
correspond to that of the seemingly analogous conserved and
immunogenic HIV-1 epitope GPGR, which constitutes the tip of
the V3 region (Figure 3A) [18] and the two HIV epitopes do not
align when comparing the amino acid sequences of gp120 and
gp125 (data not shown). It should be noted that detailed structural
information about the conformation of the V3 region is only
available for the CD4-bound form of gp120 [18]. The V3 region
could be less exposed prior to CD4 binding and might display a
different orientation in the trimer [5,7,10,51]. On the other hand,
it has also been previously demonstrated that 7C8 binding to
trimeric gp125 was not enhanced by the removal of both the V1
and V2 loops [50].
A molecular model of 7C8 in complex with trimeric
gp125 suggests sterical hindrance as a potential
mechanism, underlying its efficient capacity to neutralize
HIV-2
The program HADDOCK [52,53] was used to model possible
docking solutions between the crystal structure of the 7C8 Fab
fragment and the molecular model of monomeric gp125. It should
be noted that in order to limit bias in the docking procedure, the
entire sequence that was originally used to raise the antibodies in
mice (residues 326–341 SGRRFHSQKIINKKPR) was used as a
target for the docking of 7C8 on the molecular model of gp125.
Relevant amino-acid residues (with more than 40% accessible
Figure 2. The deep and narrow antigen-binding site of 7C8, well fitted for elongated epitopes, is highly hydrophobic. The surface of
the antigen-binding site of 7C8, displayed from the perspective of a bound antigen, is colored according to its electrostatic surface potential. To the
left, the six CDR loops that form the antigen-binding site are colored according to the sequence-panel. To the right, the relative arrangement and the
conformation of the CDRs result in the formation of a deep and narrow highly hydrophobic cleft surrounded by the prominent CDRL1, CDRH1 and
CDRH3 loops. Each side of the deep antigen-binding cleft is positively (in blue) and negatively (in red) charged, respectively, while the middle section
is highly hydrophobic. A selection of light and heavy chain residues that form the antigen-binding site are indicated in white and black, respectively.
doi:10.1371/journal.pone.0018767.g002
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docking partners on the crystal structure of 7C8. Flexibility of the
side chains and backbone of the V3 domain and the 7C8 CDRs
was allowed during the simulated annealing that formed the basis
of the final rounds of refinement [52,53]. This is likely to reflect
the expected flexibility of the V3 domain as well as the limited
conformational changes commonly observed in most CDRs upon
ligand binding [18,54,55].
Analysis of the resulting docking clusters provided two main
docking solutions. Although the relative position of 7C8 towards
gp125 was significantly different in the two docking solutions, their
antigen-binding sites bound to the same part of the V3 domain,
focusing on the epitope FHSQ (Figure 4). The two solutions could
be superposed onto a trimeric model of g125 without sterical
clashes (Figure 4). It should also be noted that no clashes were
observed when the superposition was performed following the
addition of basic glycan-structures to predicted glycosylation sides
on the trimeric gp125 model (data not shown). However, due to
the uncertainties and limitations of scoring and validation [56,57]
and the large differences between the two main solutions, we will
not provide a detailed analysis of how the 7C8 Fab fragments are
docked on gp125.
Importantly, besides enforcing the importance of the FHSQ
epitope for recognition by 7C8, the two models provide a
potential mechanism for neutralization by 7C8 as the size of
bound full IgG or Fab fragments would not allow for subsequent
engagement of the gp125 trimer with the co-receptor on the
target cell.
Concluding remarks
The three-dimensional crystal structure of the Fab fragment of
the mouse monoclonal antibody 7C8, specific for the third
hypervariable region (V3) of gp125, reveals a deep and narrow
highly hydrophobic antigen-binding cleft with architecture
appropriate for a linear epitope. The CDRH2, CDRH3 and the
CDRL1 domains border this cleft. Molecular docking analysis
provides two main clusters of solutions that both indicate the high
specificity of 7C8 to the main epitope composed by the stretch of
residues FHSQ, which are localized centrally on the V3 region of
gp125.
Figure 3. The epitope FHSQ is localized centrally on the V3-region of gp125. A) The molecular model of gp125 is very similar to its HIV-1
counterpart gp120. The conserved inner face and the more variable outer face of gp125, which includes the V3 region, are highlighted in grey and
blue, respectively. The 15-mer gp125 V3-peptide used to raise 7C8 is displayed in red. The localization and solvent exposure of the epitope GPGR on
gp120 and the epitope FHSQ on gp125 are highlighted in orange. B) A putative trimeric model of gp125 displayed with the V3 region oriented
towards the target cell indicates the accessibility and solvent exposure of the FHSQ epitope.
doi:10.1371/journal.pone.0018767.g003
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Production and purification of 7C8 Fab fragments
The production, purification and crystallization of the 7C8 Fab
fragments have been described previously [58]. Briefly, 7C8 was
expressed from hybridomas and Fab fragments were prepared
through limited digestion with papain (Sigma). The Fab fragments
were subsequently purified using size-exclusion chromatography
and concentrated to 10 mg/ml.
Crystallization of 7C8 and data collection
Crystals of 7C8 Fab fragments were obtained in 100 mM Tris-
Cl pH 8.5, 50 mM ammonium sulphate, 25% (w/v) PEG 8000
and 2.5% (v/v) PEG 400 at 20uC by hanging-drop vapor diffusion
[58]. The 7C8 crystals diffracted to a resolution of 2.7 A ˚ and
belong to space group P3221, with unit-cell parameters
a=b=100.1 A ˚, c=196.8 A ˚. The asymmetric unit contains two
7C8 molecules with a molecular mass of 47.1 kDa, giving a solvent
content of 59%. Space group and unit cell parameters were
determined using the auto-indexing option of MOSFLM [59].
Scaling and reduction of the data were performed using SCALA
from the CCP4 suite of programs [60]. Five percent of the
reflections were set aside for validation. Data-collection statistics
are summarized in Table 1.
Structure solution and refinement
The three-dimensional structure of the Fab fragment of 7C8
was solved by molecular replacement using the programs
PHASER [61] and MOLREP [62]. The atomic coordinates of
the light and heavy domains of the recombinant anti-testosterone
(3-C(4)F(5)) Fab fragment (PDB ID 1I9J; [63]), including all side
chains, were used as search models. Solutions for all domains of
the two Fab molecules in the asymmetric unit could be determined
except for one light chain. Using the solution from PHASER as a
fixed model in MOLREP, the solution for the lacking light domain
was also determined. Rigid body refinement in REFMAC5 [62]
was followed by a round of simulated annealing using the program
CNS [64]. Further restrained refinement was carried out using
REFMAC5 applying TLS parameters in the final rounds of
refinement [65,66]. Model building was performed using O [67]
and COOT [68]. Residues 127 and 132 are part of a disordered
loop and were modeled with occupancy of 0.7. The geometry of
the final model was analysed using PROCHECK [69]. The final
model consists of 869 residues. A total of 78 water molecules were
added to well-defined peaks (2.0s and greater in Fo-Fc electron
density maps) found between 2 and 4 A ˚ from oxygen or nitrogen
atoms. The final refinement statistics are listed in Table 1. The
7C8 residues were numbered according to Chothia et al., [35]
using the Abnum numbering server (http://acrmwww.biochem.
ucl.ac.uk/abs/abnum/; [70]). The elbow angle was calculated
using the program RBOW (http://proteinmodel.org/AS2TS/
RBOW/index.html; [71]). Qualitative vacuum electrostatic sur-
face potentials were evaluated through calculation of locally
averaged surface charges using the protein contact potential
visualization as implemented in Pymol (PyMOL Molecular
Graphics System, Version 1.2r1, Schro ¨dinger, LLC). All figures
were prepared using Pymol.
Figure 4. Docking simulations indicate that the antigen-binding site of 7C8 binds primordially to the FHSQ epitope on gp125.
Representation of the two docking solutions of the crystal structure of 7C8 in complex with the putative gp125 trimer. The two solutions, displayed in
cyan and grey respectively, interact mainly with the solvent-exposed FHSQ epitope. The interactions proposed by the two solutions also suggest a
mechanism for neutralization since the size of the bound molecules would not allow for subsequent engagement of the gp125 trimer to the
co-receptor on target cells.
doi:10.1371/journal.pone.0018767.g004
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A molecular model of the HIV-2 gp125 monomer (subtype
SBL6669isy; GeneBank ID J04498) was generated using the
SWISS-MODEL protein modelling server [72] based on the
published crystal structure of the V3-containing gp120 molecule
(PDB ID 2B4C; [18]). The two sequences could be well aligned
despite limited sequence identity (36%). Insertions and deletions in
the sequence of gp125 when compared to gp120 were almost
exclusively confined to loops or turns in the variable outer domain
of the molecule. The molecular model of the gp125 trimer was
created by superposing the monomer on the coordinates of a
previously published model of the HIV-1-associated gp120 trimer
[49], generously provided by Prof. Peter Kwong (Vaccine
Research Center, NIH, Bethesda, MD, USA). Despite small
differences in geometry and relative disposition of the V1/V2
loops and the V3 region, the topology of the trimer model is in
good overall agreement with the three-dimensional structures
derived from cryo-electron tomography [5,7,51].
Docking simulations
Docking was performed using the program HADDOCK
[52,53], with the default settings of the program. Initial rigid
body docking was performed from 1000 starting configurations
with the two proteins randomly oriented. The 200 docking
solutions with the lowest overall energy (score) were selected for
further development. The second stage of docking comprised
simulated annealing refinements that allowed increased flexibility
of side chain and backbone torsion angles. Water molecules were
added in the final step of docking refinement in order to optimize
surface interactions. The obtained molecular models were scored
again and grouped thereafter into clusters using an algorithm
described by Daura et al., [73], based on a 7.5 A ˚ cut-off. The
quality of the clustering was checked by visual inspection of the
two-dimensional projection of the clusters according to the
algorithm suggested by Levitt [74] and as implemented in the
CHARMM program [75]. Here each of the N structures is
associated with a point (Pi, Qi), and the parameters (Pi,Qi)
i=1,N
are optimized to minimize the function
X m
i,j
RMSDi,j{D(Pi{Pj)
2z(Qi{Qj)
2D
1=2
no 2
ð1Þ
where RMSDi,j is the root mean square deviation between
structures i and j, and the sum is over all m pairs of structures. The
clusters were ranked by their size and scores, and the two most
prominent solutions were chosen for further analysis.
Accession Numbers
The atomic coordinates and structure factors of the HIV-2-
neutralizing Fab fragment (PDB ID 3NZ8) have been deposited in
the Protein Data Bank (www.pdb.org; [76]). The coordinates of all
models described in this study will be provided upon request.
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